相关实验视频

Updated: May 5, 2026

Functionalized Spirocyclic Heterocycle Synthesis and Cytotoxicity Assay

Functionalized Spirocyclic Heterocycle Synthesis and Cytotoxicity Assay

Published on: February 9, 2021

合成和生物评估3',4',5'-Trimethoxychalcone衍生物与A549和分子洞察力通过分子对接和动力学研究分子洞察力研究

Ade Danova¹, Piyanuch Wonganan², Panupong Mahalapbutr³

¹Organic Chemistry Division, Department of Chemistry, Faculty of Mathematics and Natural Sciences, Institut Teknologi Bandung, Jl. Ganesha 10, Bandung, West Java, 40132, Indonesia.

Current medicinal chemistry

|July 3, 2025

概括

新的石墨烯衍生物对A549细胞表现出强大的抗癌活性. 分子研究证实了对EGFR-TK的稳定结合,表明其作为新型癌症治疗药物的潜力.

科学领域:

药用化学医学化学
分子生物学分子生物学
计算化学计算化学

背景情况:

之前的研究已经确定了3',4',5'-Trimethoxychalcone衍生物与B环上的3,4-异位物作为A549细胞的强有力的抑制剂.
这项研究探讨了用基和基组修改B环替代剂以增强抗癌活性.

研究的目的:

合成和评估新型3',4',5'-Trimethoxychalcone衍生物对它们对A549癌细胞系的细胞毒性作用.
通过分子对接和动力学模拟,研究这些衍生物与表皮生长因子受体氨酸激酶 (EGFR-TK) 的结合相互作用和稳定性.

主要方法:

基衍生物通过克莱森-施密特凝结合成,并使用NMR和质谱学进行表征.
用MTT测定来评估细胞毒性.
使用针对EGFR-TK的YASARA进行了分子对接和动力学模拟 (PDB ID:1M17).

主要成果:

获得了16种已知的和1种新的石墨烯衍生物. 化合物6和7的活性显著,IC50值分别为0.43微米和5.47微米.
化合物6,7和14与EGFR-TK表现出类似的结合相互作用,包括结,范德瓦尔斯力,π-π堆叠和π-相互作用.
分子动力学模拟证实了化合物6,7,14和erlotinib与EGFR-TK的稳定复合.

结论:

3',4',5'-Trimethoxychalcone衍生物对A549癌细胞系具有有前途的抗癌潜力.
观察到的与EGFR-TK的结合相互作用和稳定性支持他们进一步研究作为向抗癌剂.

关键词:

这是一种抗癌药物.欧洲农业基金会 (EGFR) 是一个基金.分子对接的分子对接.分子动力学分子动力学三甲基合体.三甲基合体.

更多相关视频

Network Pharmacology Prediction and Experimental Validation of Trichosanthes-Fritillaria thunbergii Action Mechanism Against Lung Adenocarcinoma

Network Pharmacology Prediction and Experimental Validation of Trichosanthes-Fritillaria thunbergii Action Mechanism Against Lung Adenocarcinoma

Published on: March 3, 2023

Incorporating Target Protein Structure Flexibility and Dynamics in Computational Drug Discovery Using Ensemble-Based Docking Analysis

Incorporating Target Protein Structure Flexibility and Dynamics in Computational Drug Discovery Using Ensemble-Based Docking Analysis

Published on: June 20, 2025

相关概念视频

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...